Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
about
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsCCR5 monoclonal antibodies for HIV-1 therapyHumanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infectionMonoclonal CCR5 antibody for treatment of people with HIV infectionPRO 140 (a CCR5 monoclonal antibody) for treatment in people with HIV infectionComplement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionIdentification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionEnhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kineticsLow human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cellsCell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodiesDiagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection.Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns.Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemicPhenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-DependentHIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages.Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Oral CCR5 inhibitors: will they make it through?Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma virusesPotent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linkedHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTComparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsImmunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion stateCross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.Immunotherapeutic restoration in HIV-infected individuals.Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivityOpportunities for therapeutic antibodies directed at G-protein-coupled receptors.Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.
P2860
Q21090521-A15B1AC8-90E9-4FDD-A223-11EFAF24E2BEQ22242739-490126BC-3B6E-4741-B056-385D5DE2A456Q24194805-F6F747D8-B51C-4AB7-AD0C-9F09C76CEC16Q24235689-A75BA472-87CF-4DF2-89FC-660E9960E7F0Q24239870-771133F5-01FC-4DA2-A091-C33D121ECBD4Q28766705-B14ED3E0-1FC8-4C80-AC67-CBDB256DF0C9Q29619510-D1B07516-12B7-4B6C-8682-1473CE7CB4BDQ33313394-3D02D9C7-DCD9-42E4-A2C0-21DB622C9BAAQ33429049-8C9AEE1B-F5F1-428A-8CF2-0000A02B0ACDQ33883813-FCF70118-F62B-472C-B562-2E4064725D7DQ34212555-EF0B152D-FD08-4D44-8D12-3E9C6FC63519Q34229664-19161E2F-8E22-44B0-A4AE-F3886F16E55FQ34231138-624CBB6D-90AE-4279-936C-39DE717134EDQ34648499-6EA4EA2A-B507-4F38-AA68-3B003CE31CB5Q34681455-4AA596D6-BB8D-4C18-B7C1-70657FB4D700Q34976999-FC7B34ED-4B7B-4CD9-991E-183DF88BEC24Q35077704-302DC0BB-AA3B-4E90-93A6-DE9BE1062F94Q35192915-81C6AA1C-4A86-40CC-B235-A0847B3413BCQ35686912-E0DF713C-5511-4B5D-8F31-60DFA98D51C5Q35726813-0FA9DB42-94C9-481A-9332-FDBB1E65F0A1Q35878870-3964AE5E-65D7-4174-8493-011E5E4C4E43Q35947769-F6C019D1-1073-4D46-9137-710D7107840CQ36296739-80EA45D5-EFE6-49D9-9038-ED85EA808CF3Q36298503-E6ED7139-A35A-4728-AA42-E5EAACC86846Q36458354-79134B26-6BB9-4653-A94D-AED98CB47F23Q36502557-C3F53640-8147-4579-9610-B44FDE081C85Q36540060-200B9491-C2BB-4034-BF3C-12B8CF16164DQ36900010-20772874-B8A7-4F82-8213-7D01181AA1B5Q36978861-F2435E80-C55F-47BB-8C07-FDAC9C50A076Q37233074-445380C6-72DF-4F7C-9C23-244DE4B906BCQ37250899-217C13D0-A6CB-489A-9794-93CF3D31A75FQ37256644-FDD50532-E05B-40C1-9638-A64027849389Q37356028-8C5A3E89-08DA-4A95-BE21-81D2A4803AE2Q37842335-4FDE38C3-5140-46B9-A844-B4713AAB99B7Q39098346-08130E3D-E720-49AE-BE8A-23F535A917CAQ39186710-1472DAE7-9D9D-4BC0-B1B0-F4E429899CEBQ39433833-6DCD7875-88B9-4840-ADD2-BB7414FE31F8Q40179461-E63202A4-FD68-4F85-8AC8-185BE41AE606Q40311562-4B93BFC9-F8A5-455C-80CA-2C0BD6FD8F10Q42348438-1A723E3D-E4F2-4F5E-8336-2ECE4A52481D
P2860
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Virus isolates during acute an ...... nsitivity to entry inhibitors.
@ast
Virus isolates during acute an ...... nsitivity to entry inhibitors.
@en
type
label
Virus isolates during acute an ...... nsitivity to entry inhibitors.
@ast
Virus isolates during acute an ...... nsitivity to entry inhibitors.
@en
prefLabel
Virus isolates during acute an ...... nsitivity to entry inhibitors.
@ast
Virus isolates during acute an ...... nsitivity to entry inhibitors.
@en
P2093
P2860
P50
P1433
P1476
Virus isolates during acute an ...... nsitivity to entry inhibitors.
@en
P2093
Christine Leemann
Cornelia Gujer
Gabriela Stiegler
Hermann Katinger
Leonardo Aceto
Marek Fischer
Peter Rusert
Rainer Weber
William C Olson
P2860
P304
P356
10.1128/JVI.79.13.8454-8469.2005
P577
2005-07-01T00:00:00Z